SELLAS triggers interim analysis in Phase 3 REGAL trial of GPS in AML; IDMC meeting in Jan 2025

SELLAS Life Sciences Group, Inc.

Pre-specified threshold of 60 deaths reached, triggering IDMC interim analysis.
IDMC to review efficacy, futility, and safety data from the Phase 3 REGAL trial in January 2025.
GPS is a potential new treatment for acute myeloid leukemia (AML).
Company hosted a webcast on December 10, 2024, to discuss the milestone and possible outcomes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.